Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | PF-07257876 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | PF-07257876 | Phase I | Actionable | In a Phase I trial, PF-07257876 treatment was well tolerated in patients with PD-L1 (CD274)-positive advanced solid tumors and resulted in an objective response rate of 5.6% (1/18, 1 partial response in a patient with head and neck squamous cell carcinoma) (J Clin Oncol 41, 2023 (suppl 16; abstr 2529); NCT04881045). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors. | Full reference... |